| Literature DB >> 31311164 |
Gabriela Cormick1,2,3, Jose M Belizán4.
Abstract
There are striking inequities in calcium intake between rich and poor populations. Appropriate calcium intake has shown many health benefits, such as reduction of hypertensive disorders of pregnancy, lower blood pressure particularly among young people, prevention of osteoporosis and colorectal adenomas, lower cholesterol values, and lower blood pressure in the progeny of mothers taking sufficient calcium during pregnancy. Studies have refuted some calcium supplementation side effects like damage to the iron status, formation of renal stones and myocardial infarction in older people. Attention should be given to bone resorption in post-partum women after calcium supplementation withdrawal. Mechanisms linking low calcium intake and blood pressure are mediated by parathyroid hormone raise that increases intracellular calcium in vascular smooth muscle cells leading to vasoconstriction. At the population level, an increase of around 400-500 mg/day could reduce the differences in calcium intake between high- and middle-low-income countries. The fortification of food and water seems a possible strategy to reach this goal.Entities:
Keywords: calcium; calcium intake; fortification; health; hypertensive disorders
Year: 2019 PMID: 31311164 PMCID: PMC6683260 DOI: 10.3390/nu11071606
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Dietary reference values for Calcium from different sources.
| UK (SACN) [ | USA and Canada (IOM) [ | FAO/WHO [ | European (EFSA) [ | |||||
|---|---|---|---|---|---|---|---|---|
| Age | Estimated Average Requirement (mg/day) | Recommended Nutrient Intake | Estimated Average Requirement (mg/day) | Recommended Dietary Allowance (mg/day) | Estimated Average Requirement (mg/day) | Recommended Nutrient Intake | Average Requirement (mg/day) | Population Reference Intake |
| 0–6 month | 400 | 525 | 200 (AI) | 240–300 | 300–400 | |||
| 6–12 month | 400 | 525 | 260 (AI) | 240–300 | 300–400 | 280 (AI) | ||
| 1–3 year | 275 | 350 | 500 | 700 | 500 | 390 | 450 | |
| 4–6 year | 350 | 450 | 800 | 1000 | 440 | 600 | 680 | 800 |
| 7–10 year | 425 | 550 | 800 | 1000 | 1300 | 680 | 800 | |
| Males | ||||||||
| 11–14 year | 750 | 1000 | 1100 | 1300 | 1040 | 1300 | 960 | 1150 |
| 15–18 year | 750 | 1000 | 1100 | 1300 | 1040 | 1300 | 960 | 1150 |
| 19–24 year | 525 | 700 | 800 | 1000 | 840 | 1000 | 860 | 1000 |
| 25–50 year | 525 | 700 | 800 | 1000 | 840 | 1000 | 750 | 950 |
| 50 year | 525 | 700 | 800 | 1000 | 840 | 1000/1300 | 750 | 950 |
| Females | ||||||||
| 11–14 year | 625 | 800 | 1100 | 1300 | 1040 | 1300 | 960 | 1150 |
| 15–18 year | 625 | 800 | 1100 | 1300 | 1040 | 1300 | 960 | 1150 |
| 19–24 year | 525 | 700 | 800 | 1000 | 840 | 1000 | 860 | 1000 |
| 25–50 year | 525 | 700 | 800 | 1000 | 840 | 1000 | 750 | 950 |
| 50 year | 525 | 700 | 1000 | 1200 | 840 | 1000 | 750 | 950 |
| Pregnancy | ||||||||
| 14 to 18 year | Same as non-pregnant | Same as non-pregnant | 1100 | 1300 | * | * | Same as non-pregnant | Same as non-pregnant |
| 19 and older | Same as non-pregnant | Same as non-pregnant | 800 | 1000 | 940 | 1200 | Same as non-pregnant | Same as non-pregnant |
| Lactation | plus 550 | plus 550 | 1100/800 | 1300/1000 | 1040 | 1000 | Same as non-lactating | Same as non-lactating |
SACN: UK Scientific Advisory Committee on Nutrition. IOM: USA Institute of Medicine. EFSA: European Food Safety Authority; AI: Average Intake. * No data available.
Effect of calcium intake on health outcomes. Evidence from randomised controlled trials (RCT) and systematic reviews of randomised controlled trials.
| Health Outcomes | Outcome | Population Group | Research Evidence | Effect Size |
|---|---|---|---|---|
| Hypertensive disorders of pregnancy | Preeclampsia | Pregnant women | Meta-Analysis | Calcium supplementation compared to placebo reduced the risk of preeclampsia, RR 0.45, (95% CI: 0.31 to 0.65) [ |
| Pregnant women with low basal calcium intake | Meta-Analysis | Calcium supplementation compared to placebo reduced the risk of preeclampsia, RR 0.36, (95% CI: 0.20 to 0.65) [ | ||
| High blood pressure | Pregnant women | Meta-Analysis | Calcium supplementation compared to placebo reduced the high blood pressure relative risk (RR) to 0.65, (95% CI: 0.53 to 0.81) [ | |
| Blood pressure | Blood pressure | Normotensive adults | Meta-Analysis | Calcium supplementation reduced systolic blood pressure (SBP) in adults by 1.14 mmHg (95% CI: −2.01 to −0.27) with doses of calcium 1000 to 1500 mg/day and by 2.79 mmHg (95% CI: −4.71 to −0.86) with doses of calcium equal to or over 1500 mg/day. Calcium supplementation had the greatest effect in young adults of less than 35 years as their SBP was reduced by 2.11 mmHg (95%CI: −3.58 to −0.64) [ |
| Blood pressure | Hypertensive adults | Calcium supplementation reduced SBP by −1.86 mm Hg (95% CI: −2.91 to −0.81) and diastolic BP (DBP) by −0.99 mm Hg (95% CI: −1.61 to −0.37) [ | ||
| Blood pressure | Hypertensive adults with low basal calcium intake | In people with relatively low calcium intake (≤ 800 mg per day) calcium supplementation reduced SBP by −2.63 (95% CI: −4.03 to −1.24) and DBP by −1.30 (95% CI: −2.13 to −0.47) [ | ||
| Blood pressure | Hypertensive adults | Calcium supplementation as compared to control induced a statistically significant reduction in SBP (mean difference: −2.5 mmHg, 95% CI: −4.5 to −0.6, I(2)= 42%) but not DBP (mean difference: −0.8 mmHg, 95% CI: −2.1 to 0.4, I(2) = 48%) [ | ||
| Progeny blood pressure | High blood pressure | Pregnant women/children | RCT | Calcium supplementation showed that children whose mothers received calcium supplementation had, at seven years of age, a reduction in the risk of high blood pressure (above the 90th percentile) in comparison with children whose mothers were in the placebo group (RR 0.59; 95% CI: 0.39 to 0.90) [ |
| Cholesterol | LDL and HDL Cholesterol | Adults | Meta-Analysis | Calcium supplementation reduced low-density lipoprotein (LDL) cholesterol [−0.12 mmol/L (95% CI: −0.22 to −0.02)] and increased high-density lipoprotein (HDL) cholesterol [0.05 mmol/L (95% CI: 0.00 to 0.10) [ |
| Colorectal adenomas | Recurrent colorectal adenomas | Adults with previous adenomas | Meta-Analysis | Calcium supplementation with doses from 1200 to 2000 mg/day and treatment duration from 36 to 60 months reduced the risk of recurrent colorectal adenomas, RR = 0.89, (95%CI: 0.82–0.96) [ |
| Bone health | Bone mineral density | Children | Meta-Analysis | Calcium supplementation had a small effect on total body bone mineral content (standardised mean difference 0.14, 95% CI: 0.01 to 0.27) and upper limb bone mineral density (0.14, 95% CI: 0.04 to 0.24), and this effect persisted after the end of supplementation only in the upper limb (0.14, 95% CI: 0.01 to 0.28) [ |
| Renal stones | Urolithiasis | Individuals with osteoporosis | Meta-Analysis | Calcium supplementation compared to placebo, RR 0.66 [95% CI 0.19, 2.34]; 5 studies in postmenopausal or elderly women including 2038 subjects [ |
| Urolithiasis | Pregnant women | Meta-Analysis | Calcium supplementation during pregnancy did not increase the risk of urolithiasis, RR 1.52 [95% CI: 0.06, 40.67] or renal colic, RR 1.75 [95% CI; 0.51, 5.99] in 2 studies with 12901 women [ |